Karabaglar

This research aims to compare the effects of Hatha yoga and reformer Pilates exercises on individuals with hyperkyphosis, a condition where an increased curvature of the spine leads to poor posture, back pain, balance problems, and respiratory difficulties. Hyperkyphosis is linked to muscle weakness and poor posture habits, especially in adolescents and older adults, and can impact quality of life, body image, and physical function. Participants will be assigned to one of three groups a control group performing a home exercise program, a Hatha yoga group exercising three times a week for eight weeks with sessions lasting 45 minutes led by a certified instructor focusing on postural control and breathing, or a reformer Pilates group with the same exercise frequency and session length led by a certified Pilates instructor focusing on posture. All groups receive a home program and weekly telephone follow-up during the eight-week period. During the study, participants will undergo various assessments at the start and after eight weeks, including posture evaluation scales, measurements of kyphosis angle, pain scales, balance tests, quality of life questionnaires, body image assessments, pulmonary function tests, and body composition measurements. Researchers will monitor changes in posture, pain, balance, respiratory function, body image, and quality of life. The study includes physical exams and regular follow-up to evaluate the effects of these exercise programs on hyperkyphosis.

Researchers are evaluating the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for treating pre- and postmenopausal women and men with locally advanced or metastatic estrogen receptor positive ERhuman epidermal growth factor 2 negative HER2- breast cancer who have an ESR1 mutation and have previously been treated with ribociclib or palbociclib. The study aims to compare the effectiveness, safety, and tolerability of these two treatment combinations. Participants are randomly assigned to one of two groups one receives 5 mg daily oral lasofoxifene plus oral abemaciclib 150 mg twice a day the other receives fulvestrant 500 mg via intramuscular injections on Days 1, 15, and 29 and then monthly thereafter, combined with oral abemaciclib 150 mg twice a day. This open-label study assesses these treatments over approximately three years. During the trial, participants will be monitored through regular assessments including tumor measurements, survival tracking, quality of life questionnaires, and evaluation of adverse events. Researchers will measure progression-free survival as the primary outcome and also track response rates, overall survival, treatment duration, and time to chemotherapy. Brain metastases patients meeting specific criteria are allowed, and safety is closely observed throughout the study period which may last up to about three years.

This research aims to evaluate the effects of Seladelpar on clinical outcomes in adults with Primary Biliary Cholangitis PBC who also have compensated cirrhosis. The study is a Phase 3 randomized, double-blind, placebo-controlled trial focusing on treatment outcomes for this liver condition. It is sponsored by Gilead Sciences and seeks to understand how Seladelpar may impact disease progression and survival in this specific patient group. Participants will be randomly assigned to receive either Seladelpar or a placebo daily for up to 36 months. Those with CP-A cirrhosis will take 10 mg capsules of Seladelpar, while those with CP-B cirrhosis will take 5 mg capsules. The placebo group will take one capsule daily as well. This long-term treatment period allows researchers to compare outcomes between the two groups effectively. During the study, participants will follow a schedule of assessments to monitor their health and response to the study drug. Researchers will measure outcomes such as event-free survival, overall survival, liver transplant-free survival, and time to hospitalization over 36 months. Safety and laboratory parameters will be regularly evaluated to ensure participant well-being throughout the trial.